Related references
Note: Only part of the references are listed.Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease
David J. Gibson et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Nicholas A. Kennedy et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
Christopher Andrew Lamb et al.
GUT (2019)
Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
Mark A. Samaan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration
Helena Edlund et al.
AAPS JOURNAL (2017)
American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases
Niels Vande Casteele et al.
GASTROENTEROLOGY (2017)
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases
N. Mitrev et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
French national consensus clinical guidelines for the management of Crohn's disease
Laurent Peyrin-Biroulet et al.
DIGESTIVE AND LIVER DISEASE (2017)
The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
Andres J. Yarur et al.
GUT (2016)
Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies
Casper Steenholdt et al.
INFLAMMATORY BOWEL DISEASES (2016)
Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease
Casper Steenholdt et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2016)
Transient and Persistent Antibodies Against TNF-Inhibitors in IBD
Casper Steenholdt
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Factors Associated With Short- and Long-Term Outcomes of Therapy for Crohn's Disease
Walter Reinisch et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Johannan F. Brandse et al.
GASTROENTEROLOGY (2015)
Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus
Brian Bressler et al.
GASTROENTEROLOGY (2015)
Changes in Serum Trough Levels of Infliximab During Treatment Intensification but not in Anti-infliximab Antibody Detection are Associated with Clinical Outcomes after Therapeutic Failure in Crohn's Disease
Casper Steenholdt et al.
JOURNAL OF CROHNS & COLITIS (2015)
Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial
Casper Steenholdt et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2014)
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial
Casper Steenholdt et al.
GUT (2014)
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
Freddy Cornillie et al.
GUT (2014)
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Niels Vande Casteele et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease
Casper Steenholdt et al.
THERAPEUTIC DRUG MONITORING (2013)
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
N. Vande Casteele et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease
Casper Steenholdt et al.
INFLAMMATORY BOWEL DISEASES (2012)
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)